Skip to content
  • About
  • Board
  • News
  • Sign Up
  • Contact

Visit

vjhemonc logo
VJOncology
Logo
  • Home (current)
  • Diseases
    Genitourinary
    Lung
    Head and Neck
    Breast
    Gynecological
    Skin
    View all Diseases
    • Topics
      Treatment
      Early Diagnosis
      Nursing
      Pharmacy
      Supportive Care
      Policy
      View all Topics
      • Conferences
        NCRI
        2019
        ISOPP
        2019
        ESMO
        2019
        EONS
        2019
        ASCO
        2019
        ELCC
        2019
        View all Conferences
        • Features
        • Podcasts
          • About
          • Board
          • News
          • Sign Up
          • Contact

        ALK

        2:21
        Current treatment landscape for ALK-positive NSCLC
        Marina Garassino
        3:43
        Biomarkers in NSCLC: a pathologist’s insight into PD-L1 and TMB
        Alex Haragan
        0:58
        Challenges and treatment of CNS metastases in NSCLC
        Sanjay Popat
        1:23
        Optimizing treatment of ALK+ NSCLC: clinical realities
        Silvia Novello
        1:34
        Therapy sequencing in the current NSCLC treatment landscape
        Nicolas Girard
        3:16
        Impact of new TKIs on NSCLC treatment planning
        Nicolas Girard
        1:34
        Personalized therapy in thoracic malignancies
        Dean Fennell
        4:43
        A new role for pharmacists in the personalized treatment of cancer patients?
        Christine Walko
        2:42
        Off-label medication use in lung cancer
        Federico Cappuzzo
        1:26
        Assessment and diagnostic workup for NSCLC in 2018
        Nathan Penell
        1:28
        ATLANTIC: durvalumab in the fight against NSCLC
        Marina Garassino
        2:11
        Economic impact of NGS for NSCLC diagnostics
        Nathan Penell
        3:22
        Drugs with low response rates – should they always be offered to patients?
        Jacob Kettle
        2:16
        IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
        Martin Reck
        1:25
        Treating NSCLC with CNS involvement: TKIs with high penetrance
        Marina Garassino
        1:38
        More focus is needed on subtypes of lung cancer that do not have FDA-approved targeted therapies
        Ross Camidge
        • 1
        • 2
        • 3
        • Next
        vjoncology logo VJOncology is intended for Healthcare Professionals only

        By choosing to continue, you are confirming that you are a healthcare professional

        VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

        Please enter your details if you would like to receive the latest oncology news and updates

        Continue
        Disease channels
        • Genitourinary
        • Lung
        • Head and Neck
        • Breast
        • Gynecological
        • Skin
        • View all
        Join our community

        Keep up-to-date via social media

        Sign up for email updates

        Get great new content delivered to your inbox

        Sign up
        mmp logo

        Magdalen Centre
        The Oxford Science Park
        Oxford OX4 4GA, United Kingdom

        VJOncology logo
        The content of VJOncology is intended for healthcare professionals
        • Cookie Policy
        • Privacy Policy
        • Terms of Use
        • Editorial Policy